India's Largest Drugmaker Says Slump in Generics Won't Last Long
- Decline in prices a temporary cycle, Sun Chairman Makov says
- Indian generics manufacturers could boost market share
This article is for subscribers only.
The chairman of Sun Pharmaceutical Industries Ltd., India’s largest drugmaker, said he doesn’t expect the slump in U.S. generic prices that’s roiling the global industry to last.
Pressure on prices will eventually lead to restrictions on supply that will hurt the health-care industry, Sun Pharma Chairman Israel Makov said in an interview with BloombergQuint at the World Economic Forum in Davos, Switzerland. “I see this as a temporary cycle.”